EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models

Jessica B Foster, Peter J Madsen, Kyra Harvey, Crystal Griffin, Allison Stern, Luke Patterson, Nikhil Joshi, Conor Dickson, Olivia McManus, Ezra Beaubien, Cullen Wilson, David R Beale und 7 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noaf115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Jessica B Foster und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Glioma, Immunotherapy, Adoptive, Gangliosides, Brain Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Department of Defense, National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diffuse midline glioma (DMG) and high-grade glioma are devastating pediatric central nervous system tumors that remain incurable. Recent chimeric antigen receptor (CAR) T cell studies have shown proof of concept and early signs of efficacy against DMG targeting GD2. Prior work and ongoing clinical trials have focused on using viral vectors to create permanent CAR T cells. However, virally transduced GD2-directed CAR T cells have shown significant neurotoxicity in both preclinical models and human trials.

Methods

We evaluated transient CAR T cells targeting GD2 created with mRNA, assessing for efficacy and safety in cell line, organoid, and in vivo xenograft models with repetitive intratumoral dosing.

Results

We show that mRNA GD2-directed CAR T cells are active against both cell lines and organoid models of DMG and high-grade glioma in vitro. Cytotoxicity consistently abates over 9 days, highlighting the potential to avoid toxicity from persistent T cell activity. In both pontine and thalamic DMG xenograft models, repeated doses of mRNA GD2-directed CAR T cells were titrated down to maintain therapeutic effects without causing neurologic toxicity.

Conclusions

Our results demonstrate the utility of transient mRNA CAR T cells delivered intratumorally to provide effective tumor killing with a defined half-life, allowing for modulation of the dose and potential side effects. We anticipate this study will expand the use of CAR T cell therapy for DMG and other central nervous system tumors and non-malignant disorders, where concern for toxicity from permanently expressing CAR T cells may hinder development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaImmunotherapy, AdoptiveGangliosidesBrain NeoplasmsReceptors, Chimeric AntigenRNA, MessengerT-LymphocytesHumansAnimalsXenograft Model Antitumor AssaysMiceTumor Cells, CulturedFemale

Stichwörter der Autor:innen

CAR T cellsbrain tumordiffuse midline gliomamRNApediatric

Substanzen

Gangliosidesganglioside, GD2Receptors, Chimeric AntigenRNA, Messenger

Autor:innen und Institutionen

  • Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Center for Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Division of Neurosurgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
  • Ben Towne Center for Childhood Cancer and Blood Disorder Research, Seattle Children's Research Institute, Seattle, WA, USA.

ORCID-Profile: Javad Nazarian

Förderung

  • NCI NIH HHS
  • Department of Defense
  • National Institute of Health
  • Matthew Larson Foundation
  • Liv Like a Unicorn
  • Greyson Saves Foundation
  • Kourtney Rose Foundation
  • October Saves

Zitieren

APA

Foster, J. B., Madsen, P. J., Harvey, K., Griffin, C., Stern, A., Patterson, L., Joshi, N., Dickson, C., McManus, O., Beaubien, E., Wilson, C., Beale, D. R., Baubet, V., Goel, P. N., Vitanza, N. A., Nazarian, J., Koptyra, M., Storm, P. B., & Resnick, A. C. (2025). Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf115

Vancouver

Foster JB, Madsen PJ, Harvey K, Griffin C, Stern A, Patterson L, et al. Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf115

BibTeX
@article{Foster2025,
  author = {Foster, Jessica B and Madsen, Peter J and Harvey, Kyra and Griffin, Crystal and Stern, Allison and Patterson, Luke and Joshi, Nikhil and Dickson, Conor and McManus, Olivia and Beaubien, Ezra and Wilson, Cullen and Beale, David R and Baubet, Valerie and Goel, Peeyush N and Vitanza, Nicholas A and Nazarian, Javad and Koptyra, Mateusz and Storm, Phillip B and Resnick, Adam C},
  title = {Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noaf115}
}
Kostenlos starten →